Global $17.1Bn Leukemia Therapeutics Market Forecast to 2024: Focus on CLL, ALL, CML, AML - ResearchAndMarkets.com

DUBLIN--()--The "Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

The leukemia therapeutics market is projected to reach USD 17.1 billion by 2024 from USD 12.3 billion in 2019, at a CAGR of 6.8% during the forecast period.

Market growth is largely driven by the rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) and increasing approvals of novel & innovative drugs and immunotherapies.

Chronic myeloid leukemia accounted for the largest share of the market, by type of leukemia, in 2018

Factors such as the large number of treatment options available for the treatment of CML and high incidence rate of CML are significantly driving the growth of this market. For instance, in the US, there were 20,940 CML new cases, as compared to 20,110 in 2017. In addition, the growth of this market segment is driven by the rising geriatric population and increasing funding for cancer research and the development of new therapies.

Targeted drugs & immunotherapy dominated the leukemia therapeutics market, by treatment type, in 2018

Owing to the surging demand for targeted drugs, this segment likely to dominate the market during the forecast period. Targeted drugs are most widely used owing to their fewer side effects and higher efficacy and success rate as compared to chemotherapy Owing to these factors, their sales have increased in recent years. For instance, the first FDA-approved immunotherapy for ALL by Novartis registered sales of USD 76 million in 2018 as compared to USD 6 million in 2017. Similarly, the sales for BLINCYTO by Amgen indicated for ALL increased by 37% in the fourth quarter of 2018.

North America to grow at the highest rate during the forecast period (2019-2024)

There has been a tremendous increase in cell-based research activities over the past decade. Increasing research in the field of regenerative medicine for the treatment of leukemia and growing awareness of personalized medicine have also resulted in the growth of this market. In addition to it, the growth in this market is driven by the high prevalence and incidence of leukemia and the rising geriatric population. According to the Leukemia & Lymphoma Society, an estimated 381,774 people are living with or in remission from leukemia in the US.

The Canadian government is taking various initiatives to support leukemia research and develop novel immunotherapies. For instance, in January 2016, the Canadian government announced the provision of USD 20 million to the Centre for Commercialization of Regenerative Medicine (CCRM) to help establish a stem cell therapy development facility in Toronto (Canada).

Key Market Players

The major players in this market are AbbVie (US), Bristol-Myers Squibb (US), Novartis (Switzerland, F. Hoffmann-La Roche (Switzerland), Pfizer (US), Sanofi (France), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan), and Celgene (US). Product approvals are a key strategy adopted by key players in order to enhance their dominance in this market.

Novartis is leading the global leukemia therapeutics market, owing to its strong sales channel and innovative therapies. The company invested ~17.5% of its revenue for its R&D activities. In May 2018, Novartis launched its CAR-T cell therapy for the second indication - treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma. With the innovative launch of Kymriah, Novartis is now a pioneer of leukemia immunotherapies.

Recent Developments

  • In January 2019, the EU approved BLINCYTO (blinatumomab) in patients with Philadelphia chromosome negative minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia. BLINCYTO is the first and only therapy for a minimal residual disease that has been approved by the EU.
  • In September 2018, blinatumomab received approval in Japan for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.
  • In July 2017, Celgene Corporation entered into a strategic partnership to develop and commercialize BeiGene's investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317, for patients with solid tumor cancers. In addition to it, BeiGene acquired Celgene's commercial operations in China and gained an exclusive license to commercialize Celgene China's cancer portfolio, inclusive of Vidaza.

Key Questions Addressed

  • What are the growth opportunities in the leukemia therapeutics market across major regions in the future?
  • Emerging countries have immense opportunities for the growth and adoption of leukemia therapeutics market drugs and immunotherapies. Will this scenario continue during the next five years?
  • Where will all the advancements in products offered by various companies take the industry in the mid- to long-term?
  • What are the various leukemia drugs types and treatment type and their respective market shares in the overall market?
  • What are the new trends and advancements in the leukemia therapeutics market?

Market Dynamics

Drivers

  • Rising Prevalence of Leukemia
  • Introduction of Innovative Therapies

Restraints

  • Complexities in Manufacturing

Opportunities

  • Growth Opportunities in Emerging Economies

Companies Mentioned

  • AbbVie
  • Amgen
  • Bristol-Myers Squibb
  • Celgene
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • Novartis AG
  • Pfizer
  • Sanofi
  • Takeda

For more information about this report visit https://www.researchandmarkets.com/r/mzx62h

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related Topics: Leukemia Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related Topics: Leukemia Drugs